1. Home
  2. OXLCI vs BCTXL Comparison

OXLCI vs BCTXL Comparison

Compare OXLCI & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OXLCI

Oxford Lane Capital Corp. 8.75% Notes due 2030

N/A

Current Price

$25.72

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo BriaCell Therapeutics Corp. Warrant expiring 2031

BCTXL

BriaCell Therapeutics Corp. Warrant expiring 2031

N/A

Current Price

$0.85

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
OXLCI
BCTXL
Founded
N/A
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2010
2025

Fundamental Metrics

Financial Performance
Metric
OXLCI
BCTXL
Price
$25.72
$0.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.1K
3.6K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.10
$0.61
52 Week High
$26.25
$1.40

Technical Indicators

Market Signals
Indicator
OXLCI
BCTXL
Relative Strength Index (RSI) 56.92 45.72
Support Level $25.67 $0.76
Resistance Level $25.89 $1.21
Average True Range (ATR) 0.05 0.09
MACD 0.01 -0.01
Stochastic Oscillator 80.74 47.80

Price Performance

Historical Comparison
OXLCI
BCTXL

About BCTXL BriaCell Therapeutics Corp. Warrant expiring 2031

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Share on Social Networks: